InBio CEO Lee Myoungjae Expands Company Share Purchases, Demonstrates Commitment to Responsible Management and Shareholder Value

InBio has strengthened responsible management through the CEO's purchase of company shares.

On March 19, InBio announced that CEO Myoungjae Lee had purchased 108,383 shares of common stock on the open market over the past five months. As a result of this purchase, Mr. Lee’s total shareholdings increased to 3,239,651 shares, raising his ownership stake to 29.81%. The company explained that the continued open-market purchases since the end of last year reflect confidence in corporate growth, and are measures to restore investor trust and resolve the company’s undervaluation.

On the business front, InBio is also accelerating the commercialization of new substances secured through government projects. InBio, together with the Korea Research Institute of Chemical Technology, has successfully selected a new disinfectant drug candidate as part of a project under the Ministry of Trade, Industry and Energy since 2020, and plans to begin full-scale commercial preparations starting this year. The company aims to launch products based on this new substance while also expanding into the supply of active ingredients, with the goal of becoming a supplier of these key materials.

In addition, the company has continuously strengthened its internal control systems. About four years ago, InBio introduced a document centralization system to facilitate asset management, sharing, collaboration, management system establishment, and enhanced security for corporate documents. By requiring all documents to be stored on a central server instead of personal PCs, the company has established a system to prevent information leaks, ransomware attacks, and other security incidents in advance.

A company representative stated, "This purchase of company shares demonstrates the management’s confidence in the company’s mid- to long-term growth potential and business competitiveness," adding, "This year, we will achieve tangible results based on domestically developed new substances to enhance both corporate and shareholder value."

This content was produced with the assistance of AI translation services.